Alpha Crest Capital Management LLC Tg Therapeutics, Inc. Transaction History

Alpha Crest Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$3.74 - $10.66 $25,058 - $71,422	-6,700 Reduced 7.98%	77,224 $328,000
Q1 2022 May 12, 2022	BUY	$7.81 - $20.45 $528,846 - $1.38 Million	67,714 Added 417.73%	83,924 $798,000
Q4 2021 Feb 09, 2022	BUY	$15.2 - $35.51 $246,392 - $575,617	16,210 New	16,210 $308,000
Q3 2021 Nov 10, 2021	SELL	$21.78 - $40.45 $593,004 - $1.1 Million	-27,227 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$32.5 - $48.96 $884,877 - $1.33 Million	27,227 New	27,227 $1.06 Million
Q4 2020 Feb 12, 2021	SELL	$25.27 - $54.9 $318,402 - $691,740	-12,600 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$18.49 - $27.24 $25,885 - $38,136	1,400 Added 12.5%	12,600 $337,000
Q2 2020 Aug 12, 2020	SELL	$8.9 - $21.84 $631,010 - $1.55 Million	-70,900 Reduced 86.36%	11,200 $218,000
Q1 2020 May 13, 2020	BUY	$7.14 - $15.99 $271,320 - $607,620	38,000 Added 86.17%	82,100 $808,000
Q4 2019 Feb 12, 2020	BUY	$5.1 - $11.2 $224,909 - $493,919	44,100 New	44,100 $490,000

336

87.6M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.23B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Crest Capital Management LLC with notifications on news.